Loss of CDKN2A cooperates with WWTR1(TAZ)-CAMTA1 gene fusion to promote tumor progression in epithelioid hemangioendothelioma.

Caleb N Seavey Andrea Hallett Shuo Li Kepeng Che Ajaybabu V Pobbati Shuang Ma Ashley Burtscher Ryan Kanai Janine S A Warren Brian P Rubin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

CDKN2A loss enhances the tumorigenicity of EHE in vivo and enabled the generation of. the first cell lines of this disease. These cell line replicate key facets of the human disease phenotype. Therefore, these cell lines and allograft tumors generated after implantation serve as robust model systems for therapeutic testing of compounds either directed at EHE or at other TAZ-driven cancers.

Keyphrases

endothelial cells
poor prognosis
copy number
induced pluripotent stem cells
gene expression
dna methylation